In this article, we will list the 5 Best Cheap Stocks Under $10 to Buy Now in April. Please visit 10 Best Cheap Stocks Under $10 to Buy in April, if you’d like to see an extended list and how we came up with the stocks.

5. TOYO Co., Ltd. (NASDAQ:TOYO)

PE Ratio: 10.07

TOYO Co., Ltd. (NASDAQ:TOYO) is among the best cheap stocks to buy on this list.

On March 31, TOYO released its financial results for the second half and full year ended December 31, 2025. The company reported full-year revenue of $427.4 million, surpassing prior guidance, which was driven by strong solar cell shipments of 4.5 GW, supported by the Ethiopia 4 GW facility operating at full capacity. Solar module deliveries reached 249 MW.

According to the reports, the business’s Non-GAAP adjusted net income surged to $52.2 million, a 769% increase from 2024, while EBITDA reached $95.8 million. Second-half revenue was approximately $288.3 million, with net income of $34.7 million. TOYO enters 2026 with projected solar cell shipments of 5.5–5.8 GW and adjusted net income of $90–100 million, underpinned by continued operational scale, policy-compliant technology, and a strengthened domestic and international supply chain.

Similarly, on the same day, TOYO Co., Ltd. (NASDAQ:TOYO) also announced that it appointed Rhone Resch as its new Chief Strategy Officer, a role reporting directly to the CEO. Resch will oversee global growth initiatives, focusing on expanding manufacturing, accelerating U.S. market presence, and strengthening strategic partnerships across the solar industry.

TOYO Co., Ltd. (NASDAQ:TOYO) is a Japan‑based solar technology company that designs, manufactures, and sells silicon wafers, solar cells, and photovoltaic modules, serving global renewable energy markets with vertically integrated clean energy solutions.

4. 3D Systems Corporation (NYSE:DDD)

PE Ratio: 9.82

3D Systems Corporation (NYSE:DDD) is one of the best cheap stocks to invest in.

TheFly reported on March 25 that DDD announced it obtained full-scope certification under the European Union Medical Device Regulation (EU MDR) 2017/745. This certification underscores the company’s dedication to maintaining top-tier quality and patient safety standards while enabling broader growth in the European dental market. Leveraging its established leadership in high-volume aligner production and the NextDent materials portfolio from the Vertex acquisition, 3D Systems Corporation (NYSE:DDD)’s NextDent Jetted Denture Solution offers a significant advancement in producing monolithic, multi-material prosthetics. The solution delivers enhanced aesthetics, durability, and efficiency through the company’s MultiJet Printing technology, strengthening its position in dental manufacturing.

Separately, earlier on March 9, DDD released its financial results for Q4 and full-year 2025. Fourth-quarter revenue fell 4% to $106.3 million, with Healthcare Solutions up 25% to $50.5 million and Industrial Solutions down 21% to $55.8 million. Net loss narrowed to $19.5 million, while adjusted EBITDA improved by $13.8 million.

The corporation reported that its full-year revenue declined 12% to $386.9 million, with net income rising to $29.9 million due to gains on dispositions and lower operating expenses. Adjusted EBITDA improved by $21 million. At year-end, cash totaled $97.1 million, with manageable debt maturing through 2030.

3D Systems Corporation (NYSE:DDD) is a technology company that designs and manufactures 3D printers, materials, and software for industrial and professional additive manufacturing across healthcare, aerospace, and engineering sectors.

3. Nomad Foods Limited (NYSE:NOMD)

PE Ratio: 9.14

Nomad Foods Limited (NYSE:NOMD) is among the best cheap stocks to invest in.

TheFly reported on March 30 that Deutsche Bank revised its rating on NOMD, lowering it from Buy to Hold and cutting the price target from $15 to $10. The analyst cited rising costs for oil- and energy-related inputs due to the Iran conflict, coupled with potential weakening in European consumer demand. Limited pricing flexibility and the risk of customers switching to lower-cost alternatives were highlighted as key concerns. These factors prompted the reassessment of the company’s near-term growth prospects and influenced the decision to reduce both the rating and the valuation guidance.

Separately, earlier on March 11, Nomad Foods Limited (NYSE:NOMD) announced the launch of its second Future Foods Lab initiative, the Culinary Creativity Challenge. The program seeks practical innovations that make cooking enjoyable and effortless at home, including inventive frozen meals with global flavors, customizable sauces and bases, bite-sized portions, and kitchen solutions that simplify meal preparation.

Open to startups with operational products or prototypes, the challenge offers participants access to NOMD’s European test environment, mentorship from industry experts, and opportunities for commercial scaling, co-branding, and partnerships, continuing the company’s mission to drive culinary innovation through its Future Foods Lab.

Nomad Foods Limited (NYSE:NOMD) is Europe’s largest frozen food company, manufacturing, marketing, and distributing branded frozen meals and ingredients like fish, vegetables, and ready meals across multiple European markets under iconic brands such as Birds Eye, iglo, and Findus.

2. Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH)

PE Ratio: 6.15

Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) is among the best cheap stocks under $10.

TheFly reported on March 25 that Barclays announced a reduction in AVAH price target to $9.50 from $11 while retaining an Overweight rating. The adjustment follows updates to the firm’s financial models for the healthcare facilities and managed care sector after reviewing Aveanna’s fourth-quarter results.

Earlier on March 19, Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) released its financial results for the fourth quarter and the full year of 2025. The company reported that it achieved strong operational performance, recording annual revenue growth of 20.2% and a 74.8% increase in Adjusted EBITDA, demonstrating the effectiveness of its clinical model and the commitment of its caregiving teams. Free cash flow for the year totaled $131.0 million, enhancing the company’s financial flexibility to support continued expansion.

The business emphasized that its full-year 2026 guidance does not account for any pending acquisitions. The company projects revenue in the range of $2.54 billion to $2.56 billion, with Adjusted EBITDA expected between $318 million and $322 million. These results reflect disciplined execution across all business segments and underscore AVAH’s ongoing focus on sustainable growth and operational excellence while maintaining a strong balance sheet to support strategic initiatives.

Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) is a U.S. diversified home care provider delivering pediatric and adult nursing, therapy, hospice, and medical services in patients’ homes, reducing reliance on costly hospital care while improving clinical outcomes.

1. Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

PE Ratio: 1.82

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) is among the best cheap stocks to buy.

TheFly reported on March 17 that ATRA filed a prospectus to register the potential resale of up to 400,000 common shares by HCR Molag Fund, L.P. These shares are issuable through the exercise of a warrant previously granted to HCR under an amended purchase agreement. The registration ensures compliance with the warrant’s terms but does not guarantee that HCR will sell any shares. Proceeds from any sale will go to the selling stockholder, not ATRA. Shares may be sold publicly or privately at prevailing or negotiated market prices, with HCR responsible for associated selling costs while ATRA covers registration-related expenses.

Separately, in a regulatory update, on March 12, Atara Biotherapeutics, Inc. (NASDAQ:ATRA) announced that a Type A meeting with the U.S. Food and Drug Administration has been arranged to address the complete response letter issued for the biologics license application of tabelecleucel, managed by partner Pierre Fabre Pharmaceuticals. ATRA is supporting Pierre Fabre in engaging with the FDA to collaboratively resolve the concerns outlined in the CRL. The meeting aims to discuss the additional efficacy data collected since the original submission and to facilitate a potential resubmission of the BLA, ensuring regulatory compliance and advancing the review process for tabelecleucel.

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) is a clinical‑stage biopharmaceutical company developing off‑the‑shelf T‑cell immunotherapies for cancer and autoimmune diseases to improve patient outcomes.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.